Yahoo · Oct 27, 2026
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.
IM
NASDAQ · IMMX
Immix Biopharma, Inc.
Healthcare · Biotechnology
$7.68
Down-$0.30 (-3.76%)
Updated Oct 31, 2026, 7:06 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 246.93M
- P/E ratio
- -9.97
- Dividend yield
- 0.00%
- 52-week range
- $7.56 – $15.10
- Volume
- 1.38M
- Avg. volume
- 730.89K
Price performance · IMMX
IMMX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IMMX closed at $7.68 after 21 trading sessions, down 20.66% for the selected period.
- Last close
- $7.68
- Period change
- -20.66%
- Period low
- $7.68
- Period high
- $10.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $7.86 | $8.10 | $7.56 | $7.68 | 1.38M |
| Oct 29, 2026 | $8.11 | $8.36 | $7.835 | $7.98 | 1.07M |
| Oct 28, 2026 | $7.98 | $8.21 | $7.88 | $8.125 | 1.24M |
| Oct 27, 2026 | $8.00 | $8.165 | $7.8486 | $8.05 | 1.15M |
| Oct 26, 2026 | $8.17 | $8.31 | $7.99 | $8.06 | 1.12M |
| Oct 23, 2026 | $8.34 | $8.89 | $7.88 | $8.15 | 1.2M |
| Oct 22, 2026 | $8.40 | $8.73 | $8.2301 | $8.35 | 817.97K |
| Oct 21, 2026 | $8.94 | $9.10 | $8.47 | $8.51 | 1.54M |
| Oct 20, 2026 | $8.26 | $9.03 | $8.235 | $8.91 | 1.23M |
| Oct 19, 2026 | $8.05 | $8.35 | $8.00 | $8.22 | 1.3M |
| Oct 16, 2026 | $8.67 | $8.67 | $7.95 | $7.98 | 1.5M |
| Oct 15, 2026 | $8.51 | $8.905 | $8.45 | $8.68 | 1.31M |
| Oct 14, 2026 | $8.60 | $8.87 | $8.42 | $8.51 | 1.36M |
| Oct 13, 2026 | $9.10 | $9.29 | $8.66 | $8.69 | 1.49M |
| Oct 12, 2026 | $9.42 | $9.56 | $9.18 | $9.25 | 936.25K |
| Oct 9, 2026 | $9.29 | $9.53 | $9.18 | $9.46 | 1.11M |
| Oct 8, 2026 | $9.34 | $9.37 | $8.96 | $9.29 | 1.29M |
| Oct 7, 2026 | $9.50 | $9.69 | $9.40 | $9.49 | 1.38M |
| Oct 6, 2026 | $10.20 | $10.20 | $9.515 | $9.64 | 1.22M |
| Oct 5, 2026 | $9.71 | $10.33 | $9.55 | $10.13 | 1.6M |
| Oct 2, 2026 | $10.35 | $10.37 | $9.48 | $9.68 | 2.55M |
Latest IMMX news
The latest Smart Investors Daily articles mentioning IMMX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IMMX research
Overview
Company profile and research snapshot.
Company profile
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Needham | Buy | — |
| Sep 15, 2026 | Mizuho | Outperform | — |
| Aug 11, 2026 | Morgan Stanley | Overweight | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 22, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
Immix Biopharma is back in focus as fresh Street research refines price targets that now range from US$19 to US$30. Analysts link higher targets, such as US$26 and US$30, to updated views on NXC-201, while lower figures around US$19 reflect caution on funding needs, dilution from recent equity raises, and execution risk. Read on to see how these shifting targets feed into the evolving Immix Biopharma story and how you can track the narrative from here. Stay updated as the Fair Value for Immix...
Yahoo · Oct 5, 2026
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixB
Yahoo · Oct 5, 2026
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Immix Biopharma (NASDAQ:IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy. AL amyloidos
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
